免疫球蛋白替代治疗对多发性骨髓瘤低丙种球蛋白血症和感染的真实世界有效性
本研究基于Mass General Brigham研究患者数据登记库,回顾性纳入2010年1月1日及以后确诊的6062例成人多发性骨髓瘤患者,评估免疫球蛋白替代治疗(IgRT)对低丙种球蛋白血症和感染的真实世界有效性。结果显示,IgRT启动后3个月感染 odds 显著低于启动前(OR 0.71,95%CI 0.56-0.89,P=0.0004),且IgRT启动后低丙种球蛋白血症患者显著减少。
要点
- 6062例多发性骨髓瘤患者中471例(7.8%)接受至少1次IgRT。
- IgRT启动后3个月感染 odds 显著低于启动前(OR 0.71,95%CI 0.56-0.89,P=0.0004)。
- 3231例有IgG检测的患者中2075例(64.2%)发生低丙种球蛋白血症,IgRT启动后显著减少。
核心结论
- IgRT使用与低丙种球蛋白血症和感染的显著减少相关。
- 作者认为,尽管IgRT目前用于多发性骨髓瘤治疗,但存在优化其给药剂量和治疗持续时间的潜力,以减少感染相关的发病率和死亡率。
研究设计与样本
- 回顾性研究,使用Mass General Brigham研究患者数据登记库,纳入2010年1月1日及以后确诊的成人多发性骨髓瘤患者。
- 共识别6062例多发性骨髓瘤患者(56.2%男性;中位年龄65.0岁)。
- 比较IgRT启动前后的感染;采用广义估计方程逻辑回归模型计算比值比(OR)和95%置信区间(CI)。
- 在可获得血清蛋白电泳(SPEP)结果的患者中,由自然语言处理程序支持提取免疫球蛋白G(IgG)数据,比较IgRT启动前后的IgG评估和低丙种球蛋白血症(定义为IgG水平<500 mg/dL)发生率。
主要发现
- 6062例患者中471例(7.8%)接受至少1次IgRT给药。
- IgRT启动后3个月感染 odds 显著低于IgRT启动前(OR 0.71;95%CI 0.56-0.89;P=0.0004)。
- 在可获得SPEP结果的患者(n=3405)中,3231例(94.9%)接受至少1次IgG检测,每例患者IgG检测中位数为18.0次(四分位距7.0-40.0)。
- 在3231例接受至少1次IgG检测的患者中,2075例(64.2%)发生低丙种球蛋白血症。
- IgRT启动后发生低丙种球蛋白血症的患者显著减少。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study assessed the real-world effectiveness of immunoglobulin replacement therapy (IgRT) for treatment of hypogammaglobulinemia and infections in patients with multiple myeloma (MM). A retrospective study was conducted on adult patients diagnosed with MM on or after 1 January 2010 using the Mass General Brigham Research Patient Data Registry. Infections were compared before and after IgRT initiation. Generalized estimating equation logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). In patients with accessible serum protein electrophoresis (SPEP) test results, a Natural Language Processing program supported the extraction of immunoglobulin G (IgG) data. The IgG assessments and incidence of hypogammaglobulinemia (defined as IgG level <500 mg/dL) were compared before and after IgRT initiation. The results were reported using descriptive statistics. A total of 6062 patients with MM were identified (56.2% male; median age, 65.0 years). Of the 6062 patients, 471 (7.8%) received ≥1 IgRT administrations. At 3 months, significantly lower odds of infections (OR, 0.71; 95% CI, 0.56-0.89; P = .0004) were observed after IgRT initiation than before IgRT. Among patients with accessible SPEP results (n = 3405), 3231 (94.9%) underwent ≥1 IgG test with a median of 18.0 (interquartile range, 7.0-40.0) IgG tests per patient. Hypogammaglobulinemia was experienced by 2075 of the 3231 patients (64.2%) who had ≥1 IgG test. Significantly fewer patients had hypogammaglobulinemia after IgRT initiation. In conclusion, IgRT use was associated with significant reductions in hypogammaglobulinemia and infections. Although IgRT is currently used for MM treatment, there is potential to optimize its dosing and treatment duration to reduce the morbidity and mortality associated with infections.
引用
- O'Donnell E, Gift T, Yousif Z, et al. Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma. Blood Adv. 2025. PMID: 40305667. doi:10.1182/bloodadvances.2024015477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。